PHAXIAM Reports Third-Quarter 2024 Financial Information

13 Nov 2024 17:45 CET

• Cash and cash equivalents of €5.7 million as of September 30, 2024
• Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025

Lyon (France), November 13, 2024, at 5:45 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today reports its financial results for the third quarter of 2024.

"The third quarter of 2024 was marked by the steady execution of our clinical roadmap. Our recent efforts have culminated in the U.S. FDA approval of the GLORIA Phase II study protocol, the first global bacteriophage study targeting prosthetic joint infections related to Staphylococcus aureus. We are actively working on the launch of patients recruitment for this strategic study in the first quarter of 2025, as planned. Financially, the funds raised in June 2024 have extended our cash runway until March 2025. We continue to assess new financing opportunities to further strengthen our financial structure and we remain confident in the execution of our strategy, which aims to establish PHAXIAM as a global leader in phage therapy for high value indications." stated Thibaut du Fayet, Chief Executive Officer of PHAXIAM.

THIRD-QUARTER 2024 FINANCIAL INFORMATION

On July 1, 2024, with the settlement-delivery of a €7.8 million capital increase, PHAXIAM's cash position increased by a net €6.8 million, after deduction of associated costs.

As of September 30, 2024, PHAXIAM reported cash and cash equivalents of €5.7 million, compared with €1.5 million as of June 30, 2024.

The Company estimates that this level of cash can fund its existing programs and expected operating expenses until March 2025. The Company is exploring all available options to extend its cash runway, including cost reduction measures, non-dilutive national and European funding, strategic and institutional investors commitments, etc.

KEY MILESTONES EXPECTED IN THE NEXT 12 MONTHS

• Clinical outcomes from updated compassionate real-life treatments and the PhagoDAIR pilot study, expected before the end of 2024
• Phase II (PHRC) study in Diabetic Foot Ulcer (DFU): first patient enrollment expected in the fourth quarter of 2024
• GLORIA Global Phase II study: clearance (CTA) from European and UK (MHRA) regulatory authorities to initiate patient enrollment in Europe
• Preliminary results from the Phase I pharmacokinetic study in endocarditis expected around mid-2025

About PHAXIAM Therapeutics

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.phaxiam.com

Contacts

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical programs, development plans, business and regulatory strategy and anticipated future performance of PHAXIAM and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond PHAXIAM's control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Investor should carefully read the risk factors section of the Company which can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), including in the Company’s 2023 Universal Registration Document (Document d’Enregistrement Universel) filed with the AMF on April 5, 2024 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. PHAXIAM disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in PHAXIAM’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

Attachment

• PR_PHAXIAM_13112024_Q3 2024_ENG